Cassava Sciences Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Los beneficios de Cassava Sciences han disminuido a una tasa media anual de -60.8%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 1.7% anualmente.
Información clave
-55.0%
Tasa de crecimiento de los beneficios
-46.3%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 6.0% |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera | -60.9% |
| Margen neto | n/a |
| Última actualización de beneficios | 31 Mar 2024 |
Actualizaciones de resultados anteriores recientes
No hay actualizaciones
Recent updates
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Oct 17
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Jul 04We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate
Mar 05Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Nov 19Cassava Sciences begins extension study of Alzheimer's drug simufilam
Oct 13Cassava Sciences Stock: Huge Returns Or Catastrophic Losses
Sep 29Cassava Sciences: Trying To Manage Expectations
Sep 21Cassava Sciences reaches over five-month high on rising volumes
Sep 09Cassava Sciences Looks As Good Of A Purchase As Ever
Sep 03Cassava Sciences stock jumps 10% after director buys $860K shares
Aug 26Cassava Sciences rally continues as stock up 39%
Aug 17Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results
Aug 11Cassava Sciences GAAP EPS of -$0.48 misses by $0.06
Aug 03We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Aug 03Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug
Jul 27Cassava Sciences And Alzheimer's Disease: A Precipitious Path
Jun 10Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate
May 31Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait
Apr 193 Key Points To Remember About Cassava Sciences
Apr 07Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences
Mar 31Cassava Sciences: Why The Stock Is Rangebound
Feb 28The FDA Deals Another Blow To Cassava Sciences' Bears
Feb 11Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity
Feb 02INmune Bio, The Biotech In My Stable For After Cassava Sciences
Jan 17Cassava Sciences, Inc. - The Short Squeeze Has Started
Jan 06Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam
Dec 30Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth
Dec 28Cassava Sciences Stock: Here We Go Again
Dec 21Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing
Dec 02Cassava Sciences Gets Underway Putting Simufilam To The Test
Nov 24Cassava Sciences: Data Rules!
Nov 17Cassava Sciences' Hypothesis Raises Doubts
Nov 08Cassava Sciences Stock: Massive Potential Marred By Controversy
Nov 01Cassava Sciences: Welcome To The Casino
Oct 25Has Cassava Sciences Put Out The Fire For Now?
Sep 28Cassava Sciences: Medical History In The Making
Sep 21Cassava Sciences: One Doubtful Drug For One Doubtful Indication
Sep 15We Think Cassava Sciences (NASDAQ:SAVA) Can Afford To Drive Business Growth
Sep 14More On Cassava Sciences' Controversy
Sep 04Cassava Sciences Likely To Survive Latest Attack On Alzheimer's Drug, But Caveat Emptor
Aug 26Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Cassava Sciences. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -48 | 16 | -6 |
| 31 Dec 23 | 0 | -97 | 17 | 0 |
| 30 Sep 23 | 0 | -95 | 16 | 0 |
| 30 Jun 23 | 0 | -90 | 14 | 0 |
| 31 Mar 23 | 0 | -83 | 13 | 0 |
| 31 Dec 22 | 0 | -76 | 12 | 0 |
| 30 Sep 22 | 0 | -71 | 13 | 0 |
| 30 Jun 22 | 0 | -61 | 12 | 0 |
| 31 Mar 22 | 0 | -46 | 10 | 0 |
| 31 Dec 21 | 0 | -32 | 8 | 0 |
| 30 Sep 21 | 0 | -21 | 5 | 0 |
| 30 Jun 21 | 0 | -13 | 4 | 0 |
| 31 Mar 21 | 0 | -9 | 4 | 0 |
| 31 Dec 20 | 0 | -6 | 4 | 0 |
| 30 Sep 20 | 0 | -5 | 3 | 0 |
| 30 Jun 20 | 0 | -4 | 3 | 0 |
| 31 Mar 20 | 0 | -4 | 3 | 0 |
| 31 Dec 19 | 0 | -5 | 3 | 0 |
| 30 Sep 19 | 0 | -4 | 3 | 0 |
| 30 Jun 19 | 0 | -4 | 3 | 0 |
| 31 Mar 19 | 0 | -6 | 3 | 0 |
| 31 Dec 18 | 0 | -7 | 4 | 0 |
| 30 Sep 18 | 0 | -8 | 4 | 0 |
| 30 Jun 18 | 0 | -10 | 4 | 0 |
| 31 Mar 18 | 0 | -11 | 4 | 0 |
| 31 Dec 17 | 0 | -12 | 4 | 0 |
| 30 Sep 17 | 0 | -12 | 5 | 0 |
| 30 Jun 17 | 0 | -13 | 5 | 0 |
| 31 Mar 17 | 0 | -12 | 5 | 0 |
| 31 Dec 16 | 0 | -15 | 6 | 0 |
| 30 Sep 16 | 0 | -17 | 5 | 0 |
| 30 Jun 16 | 0 | -17 | 6 | 0 |
| 31 Mar 16 | 0 | -17 | 6 | 0 |
| 31 Dec 15 | 0 | -14 | 5 | 0 |
| 30 Sep 15 | 0 | -12 | 5 | 0 |
| 30 Jun 15 | 0 | -12 | 5 | 0 |
| 31 Mar 15 | 0 | -12 | 5 | 0 |
| 31 Dec 14 | 0 | -12 | 5 | 0 |
| 30 Sep 14 | 35 | 23 | 5 | 0 |
| 30 Jun 14 | 37 | 26 | 5 | 0 |
| 31 Mar 14 | 39 | 29 | 5 | 0 |
| 31 Dec 13 | 41 | 32 | 5 | 0 |
| 30 Sep 13 | 8 | -3 | 6 | 0 |
| 30 Jun 13 | 9 | -4 | 7 | 0 |
Ingresos de calidad: SAVA actualmente no es rentable.
Margen de beneficios creciente: SAVA actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: SAVA no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 60.8% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de SAVA en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: SAVA no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (-6.8%).
Rentabilidad financiera
Alta ROE: SAVA tiene una rentabilidad financiera negativa (-70.72%), ya que actualmente no es rentable.